Efficacy of Bedaquiline Containing Regimen In MDR/XDR Tuberculosis Patients

International Journal of Medical Science

© 2021 by SSRG - IJMS Journal

Volume 8 Issue 8

Year of Publication : 2021

Authors : Santosh Kumar, Gajendra Vikram Singh, Achal Singh, Sachin Kumar Gupta

10.14445/23939117/IJMS-V8I8P101

How to Cite?

Santosh Kumar, Gajendra Vikram Singh, Achal Singh, Sachin Kumar Gupta, "Efficacy of Bedaquiline Containing Regimen In MDR/XDR Tuberculosis Patients," SSRG International Journal of Medical Science, vol. 8,  no. 8, pp. 1-7, 2021. Crossref, https://doi.org/10.14445/23939117/IJMS-V8I8P101

Abstract:

A. Introduction: India is the highest drug resistant tuberculosis (DR-TB) burden country. Outcomes of treatment for DR-TB are poor demanding new drug regimen for better outcome. Bedaquiline is the first antitubercular drug with novel mechanism of action developed specifically for treatment of DR-TB and has been shown efficacious.

B. Aim: To evaluate efficacy of bedaquiline containing regimen in MDR/XDR tubercular patients.

C. Method: An observational prospective study was conducted on 98 patients. Eligible patients were prescribed bedaquiline containing regimen and were monitored with strict adherence to follow up schedule for microbiological, clinical improvement and outcome during the treatment.

D. Result: In this study efficacy of bedaquiline containing regimen was observed in terms of increment in mean body weight, sputum culture conversion rate and treatment outcome at 6 and 12 months. Clinically significant increment in mean body weight occurred over period of 12 month. Culture conversion rate were 81.63% at 3m, 86.73% at 6m and 82.65% patients remain culture converted at end of 12m.At end of study period, 3 were culture reverted, 3 lost to treatment follow up and 8 died.

E. Conclusion: Bedaquiline containing regimen is associated with higher, faster sputum culture conversion rate. Early sputum culture conversion, high body mass index (BMI) and better immunity improve outcomes of treatment whereas extensive lung disease and low immunity negatively affects the outcome.

Keywords:

Bedaquiline, BMI, Culture Conversion, Efficacy, MDR, XDR

References:

[1] Use of high burden country lists for TB by WHO in post-2015 era; Accessedhttps://www.who.int
[2] National Tuberculosis Elimination Programme ,Indian TB report 2020:Central TB Division Ministry of Health and Family Welfare ,www.tbcindia.gov.in
[3] Global Tuberculosis Report 2018. World Health Organization 2018 Accessedhttps://www.who.int/tb/publications/global_report/tb18_ExecSum_web
[4] Annual Status Report. India TB Report 2018. Central TB Division, Ministry of Health and Family Welfare, Government of India; 2018. https://tbcindia.gov.in/showfile.php?lid¼3314. Accessed 20.02.19.
[5] Harmanjit S, Navreet Kaur N, Nipunjot G, et al. Bedaquiline: a new weapon against MDR and XDR-TB. Int J Basic ClinPharmacol. 2(2) (2013) 96–102.
[6] Matteelli A, Carvalho ACC, Dooley KE, et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 5(6) (2010) 849–858.
[7] Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant Mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 283(37) (2008) 25273–25280.
[8] Sandip V. Barvaliya, Mira K. Desai, Jigar R. Panchal, Rajesh N. Solanki. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Indian Journal of Tuberculosis, 67(2) (2020) 222-230, ISSN 0019-5707, https://doi.org/10.1016/j.ijtb.2020.03.002.
[9] Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drugresistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tubercul Lung Dis. 19(8) (2015) 979e985.
[10] Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 5 (2014) 1230e1239.
[11] Sarin R, Singla N, Vohra V, RupakSingla, Puri M.M., Munjal S, Khalid U.K., Myneedu V.P., Verma A K, Mathuria K.K., Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India, Indian Journal of Tuberculosis, 66(1) (2019) 209-213, ISSN 0019-5707, https://doi.org/10.1016/j.ijtb.2019.02.009.(http://www.sciencedirect.com/science/article/pii/S0019570719300757)
[12] Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. EurRespir J. 47(2) (2016) 564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2. PMID: 26647431.
[13] Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 60(2) (2015) 188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15. PMID: 25320286.
[14] V.S. Salhotra , K.S. Sachdeva , NeelimaKshirsagar et al, Bedaquiline CAP Site Teams. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug resistant tuberculosis in India: An interim analysis. The Indian Journal of Tuberculosis 67(1) (2020) 29-37. Doi: 10.1016/j.ijtb.2019.10.002
[15] Skrahina A, Hurevich H, Falzon D, Zhilevich L, Rusovich V, Dara M, Setkina S. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience. Int J Mycobacteriol. Suppl 1 (2016) S62-S63. doi: 10.1016/j.ijmyco.2016.11.014. Epub 2016 Nov 23. PMID: 28043617.
[16] Sandip V. Barvaliya, Mira K. Desai, Jigar R. Panchal, Rajesh N. Solanki. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Indian Journal of Tuberculosis,Volume 67, Issue 2, 2020, Pages 222-230, ISSN 0019-5707, https://doi.org/10.1016/j.ijtb.2020.03.002
[17] Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 371 (2014) 723-32. https://doi.org/10.1056/NEJMoa1313865
[18] Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. EurRespir J. 49(5) (2017) 1700387. doi: 10.1183/13993003.00387-2017. PMID: 28529205.
[19] Harmanjit S, Navreet Kaur N, Nipunjot G, et al. Bedaquiline: a new weapon against MDR and XDR-TB. Int J Basic ClinPharmacol. 2(2) (2013) 96–102.
[20] Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis. 18(11) (2014) 1315–1318.
[21] Lewis JM, Hine P, Walker J, et al. First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. EurRespir J. 47 (2016) 1581–1584.
[22] Van Heeswijk R P, Dannemann B, Hoetelmans R M. Bedaquiline: a review of 417 human pharmacokinetics and drug-drug interactions. J AntimicrobChemother 418 2014;69(9):2310-8.
[23] Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 9(3) (2009) 153e161.
[24] Ahuja SD, Ashkin D, Avendano M, et al. Multidrug-resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9, e1001300.
[25] Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 5 (2014) 1230e1239.
[26] Bonnet M, Bastard M, Du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis. 2016;20:177e186.
[27] World Health Organization. Global Tuberculosis Report, 2016. Geneva, Switzerland: WHO; 2016. WHO/HTM/TB.2016.